Top

Cancer Causes & Control

Published in:

01-03-2018 | Original paper

Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes

Authors: Tomi F. Akinyemiju, Gurudatta Naik, Kemi Ogunsina, Daniel T. Dibaba, Neomi Vin-Raviv

Published in: Cancer Causes & Control | Issue 3/2018

Abstract

Background

This study examines whether racial disparities in hospitalization outcomes persist between African–American and White women with ovarian cancer after matching on demographic, presentation, and treatment factors.

Methods

Using data from the Nationwide Inpatient Sample database, 5,164 African–American ovarian cancer patients were sequentially matched with White patients on demographic (e.g., age, income), presentation (e.g., stage, comorbidities), and treatment (e.g., surgery, radiation) factors. Racial differences in-hospital length of stay, post-operative complications, and in-hospital mortality were evaluated using conditional logistic regression models.

Results

White ovarian cancer patients had relatively higher odds of post-operative complications when matched on demographics (OR 1.35, 95% CI 1.05, 1.74), and presentation (OR 1.28, 95% CI 1.00, 1.65) but not when additionally matched on treatment (OR 1.03, 95% CI 0.78, 1.35). African–American patients had longer in-hospital length of stay (6.96 ± 7.21 days) compared with White patients when matched on demographics (6.37 ± 7.07 days), presentation (6.48 ± 7.16 days), and treatment (6.53 ± 7.59 days). Compared with African–American patients, White patients experienced lower odds of in-hospital mortality when matched on demographics (OR 0.78, 95% CI 0.66, 0.92), but this disparity was no longer significant when additionally matched on presentation (OR 0.88, 95% CI 0.75, 1.04) and treatment (OR 0.95, 95% CI 0.81, 1.12).

Conclusion

Racial disparities in ovarian cancer hospitalization outcomes persisted after adjusting for demographic and presentation factors; however these differences were eliminated after additionally accounting for treatment factors. More studies are needed to determine the factors driving racial differences in ovarian cancer treatment in otherwise similar patient populations.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:1:7–30CrossRef

Farley J, Risinger JI, Rose GS, Maxwell GL (2007) Racial disparities in blacks with gynecologic cancers. Cancer 110(2):234–243. https://doi.org/10.1002/Cncr.22797 CrossRefPubMed

Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS (2008) Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 97(2):103–107. https://doi.org/10.1002/Jso.20932 CrossRefPubMed

Terplan M, Schluterman N, Mcnamara EJ, Tracy JK, Temkin SM (2012) Have racial disparities in ovarian cancer increased over time? An analysis of seer data. Gynecol Oncol 125(1):19–24. https://doi.org/10.1016/J.Ygyno.2011.11.025 CrossRefPubMed

Brewer KC, Peterson CE, Davis FG, Hoskins K, Pauls H, Joslin CE (2015) The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois. Ann Epidemiol 25(8):556–563. https://doi.org/10.1016/J.Annepidem.2015.03.021 CrossRefPubMedPubMedCentral

Terplan M, Smith EJ, Temkin SM (2009) Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control 20(7):1139–1150. https://doi.org/10.1007/S10552-009-9322-2 CrossRefPubMed

Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21(18):3488–3494. https://doi.org/10.1200/Jco.2003.01.061 CrossRefPubMed

Randall TC, Armstrong K (2016) Health care disparities in hereditary ovarian cancer: are we reaching the underserved population? Current treatment options in oncology 17(8):39. https://doi.org/10.1007/S11864-016-0417-1 CrossRefPubMed

Bristow RE, Powell MA, Al-Hammadi N et al (2013) Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105(11):823–832. https://doi.org/10.1093/Jnci/Djt065 CrossRefPubMedPubMedCentral

10.

Terplan M, Temkin S, Tergas A, Lengyel E (2008) Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 111(2):173–178. https://doi.org/10.1016/J.Ygyno.2008.08.013 CrossRefPubMedPubMedCentral

11.

Morris CR, Sands MT, Smith LH (2010) Ovarian cancer: predictors of earlystage diagnosis. Cancer Causes Control 21:1203–1211. https://doi.org/10.1007/S10552-010-9547-0 CrossRefPubMed

12.

National Cancer Institute (2015) Seer stat fact sheets: ovary cancer. http://Seer.Cancer.Gov/Statfacts/Html/Ovary.Html

13.

Peterson C, Rauscher G, Johnson T, Kirschner C, Barrett R, Kim S et al (2014) The association between neighborhood socioeconomic status and ovarian cancer tumor characteristics. Cancer Causes Control 25(5):633–637CrossRef

14.

Bristow RE, Zahurak ML, Ibeanu OA (2011) Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 121:364–368. https://doi.org/10.1016/J.Ygyno.2010.12.347 CrossRefPubMed

15.

Parham G, Phillips JL, Hicks ML, Andrews N, Jones WB, Shingleton HM et al (1997) The national cancer data base report on malignant epithelial ovarian carcinoma in African-American Women. Cancer 80:816–826CrossRef

16.

Goff BA, Matthews BJ, Larson EH, Andrilla CHA, Wynn M, Lishner DM et al (2007) Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109:2031–2042. https://doi.org/10.1002/Cncr.22604 CrossRefPubMed

17.

Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H (2015) Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 125:833–842. https://doi.org/10.1097/Aog.0000000000000643 CrossRefPubMedPubMedCentral

18.

Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE (2015) Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 212:E1–E9. https://doi.org/10.1016/J.Ajog.2014.10.1104 CrossRef

19.

Hodeib M, Chang J, Liu F, Ziogas A, Dilley S, Randall LM et al (2015) Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol 138:121–127. https://doi.org/10.1016/J.Ygyno.2015.04.011 CrossRefPubMedPubMedCentral

20.

Howell EA, Egorova N, Hayes MP, Wisnivesky J, Franco R, Bickell N (2013) Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol 122:1025–1032. https://doi.org/10.1097/Aog.0b013e3182a92011 CrossRefPubMed

21.

Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH (2014) Gynecologic cancer disparities: a report from the health disparities taskforce of the society of gynecologic oncology. Gynecol Oncol 133:353–361. https://doi.org/10.1016/J.Ygyno.2013.12.039 CrossRefPubMedPubMedCentral

22.

Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627. https://doi.org/10.1200/Jco.2006.10.2517 CrossRefPubMed

23.

Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL (2009) Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel:an analysis of Gynecologic Oncology Group Trials. Cancer 115:4210–4217. https://doi.org/10.1002/Cncr.24482 CrossRefPubMedPubMedCentral

24.

NCI Surveiilance Eaerp (2017) Cancer of the ovary—cancer stat facts. Secondary cancer of the ovary—cancer stat facts 2017. https://seer.cancer.gov/statfacts/html/ovary.html

25.

AHRQ (Agency For Healthcare Research And Quality) R M. Hcup Databases, Healthcare Cost And Utilization Project (Hcup). February 6,2017 Ed: Ahrq (Agency For Healthcare Research And Quality), 2011

26.

Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-Cm administrative databases. J Clin Epidemiol 45(6):613–619CrossRef

27.

NCCN Clinical Practice Guidelines in Oncology. Nccn.Org. N.P (2017) https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian. Accessed 21 Mar 2017

28.

Silber JH et al (2014) Racial disparities in colon cancer survival. Ann Intern Med 161(12):845. https://doi.org/10.7326/M14-0900 CrossRefPubMed

29.

Naik G, Akinyemiju T (2017) Disparities in hospitalization outcomes among African-American and white prostate cancer patients. Cancer Epidemiol 46:73–79. https://doi.org/10.1016/J.Canep.2016.12.001 Epub 2017 Jan 3.CrossRefPubMed

30.

Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310(4):389–397CrossRef

31.

Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA (2016) Ovarian cancer outcomes: predictors of early death. Gynecol Oncol 140(3):474–480. https://doi.org/10.1016/J.Ygyno.2015.12.021 CrossRefPubMed

32.

Suidan RS, Leitao MM Jr, Zivanovic O et al (2015) Predictive value of the age-adjusted charlson comorbidity index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol 138(2):246–251. https://doi.org/10.1016/J.Ygyno.2015.05.034 CrossRefPubMedPubMedCentral

33.

Elit L, Charles C, Gold I et al (2003) Women’s perceptions about treatment decision making for ovarian cancer. Gynecol Oncol 88(2):89–95CrossRef

34.

John EM, Whittemore AS, Harris R, Itnyre J (1993) Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S.case–control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85(2):142–147CrossRef

35.

Pan HY, Walker GV, Grant SR et al (2017) Insurance status and racial disparities in cancer-specific mortality in the United States: a population-based analysis. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.Epi-16-0976 CrossRef

36.

Halpern MT et al (2008) Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Obstet Gynecol Surv 63(6):380–381CrossRef

37.

Murphy CC et al (2015) Race and insurance differences in the receipt of adjuvant chemotherapy among patients with stage III colon cancer. J Clin Oncol 33(23):2530–2536CrossRef

38.

Hoehn RS et al (2015) Does race affect management and survival in hepatocellular carcinoma in the United. States? Surgery 158(5):1244–1251CrossRef

39.

Fedewa SA et al (2011) Insurance status and racial differences in uterine cancer survival: a study of patients in the national cancer database. Gynecol Oncol 122(1):63–68CrossRef

40.

Costa LJ, Brill IK, Brown EE (2016) Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer 122(20):3183–3190CrossRef

41.

Gerhard RS et al (2017) Treatment of men with high-risk prostate cancer based on race, insurance coverage,and access to advanced technology. Urol Oncol. https://doi.org/10.1016/J.Urolonc.2016.12.004 CrossRefPubMedPubMedCentral

42.

Cholankeril G et al (2016) Skilled nursing facility placement in hospitalized elderly patients with colon cancer. Eur J Surg Oncol 42(11):1660–1666CrossRef

43.

Alhilli MM et al (2013) Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients. J Am Coll Surg 217(3):507–515CrossRef

44.

Balentine CJ et al (2014) Association of high-volume hospitals with greater likelihood of discharge to home following colorectal surgery. JAMA Surg 149(3):244CrossRef

45.

Tsai TC, Orav EJ, Joynt KE (2014) Disparities in surgical 30-day readmission rates for medicare beneficiaries by race and site of care. Ann Surg 259(6):1086–1090CrossRef

46.

Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, Hershman DL (2017) Association of hospital volume and quality of care with survival for ovarian cancer. Obstet Gynecol 130(3):545–553. https://doi.org/10.1097/Aog.0000000000002164 CrossRefPubMedPubMedCentral

Title: Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes
Authors: Tomi F. Akinyemiju
Gurudatta Naik
Kemi Ogunsina
Daniel T. Dibaba
Neomi Vin-Raviv
Publication date: 01-03-2018
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 3/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-018-1010-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Non-communicable chronic diseases and timely breast cancer screening among women of the Eastern Caribbean Health Outcomes Research Network (ECHORN) Cohort Study

Geospatial approaches to cancer control and population sciences at the United States cancer centers

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort

Feasibility of analyzing DNA copy number variation in breast cancer tumor specimens from 1950 to 2010: how old is too old?

Participatory implementation science to increase the impact of evidence-based cancer prevention and control

Keynote webinar | Spotlight on antibody–drug conjugates in cancer